Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Technetium-99m ethylene dicysteine (99mTc-EC) is a small molecule radiopharmaceutical used as a renal tubular function tracer in nuclear medicine. It is a metabolite of ethylene cysteine dimer (ECD) and was developed as an alternative to ortho-iodohippurate (OIH) and technetium-99m mercaptoacetyltriglycine (MAG3). 99mTc-EC is primarily eliminated from the body through active tubular transport in the kidneys, making it highly effective for assessing effective renal plasma flow (ERPF) and tubular function. It is particularly useful in evaluating patients with renal failure, suspected obstructive nephropathy, renovascular disorders, and monitoring renal transplants. The agent is typically prepared from a lyophilized kit at room temperature and exhibits high stability for at least 8 hours post-preparation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on technetium-99m ethylene dicysteine.